Results 171 to 180 of about 224,084 (299)

Quantum computing applications in drug discovery. [PDF]

Brief Bioinform
Li J, Wei L, Tong HHY, Zou Q.
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Quantum Computing and Quantum Technologies in Drug Discovery and Therapeutics: Evidence, Benchmarking, and Translational Integration. [PDF]

Drug Des Devel Ther
Niazi SK.
europepmc   +1 more source

DNA methylation and expression of MAPRE3 affect overall survival of early‐stage non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
Both cg12821679MAPRE3 methylation and MAPRE3 expression are significantly associated with overall survival (OS) of non‐small cell lung cancer. Meanwhile, MAPRE3 expression significantly modified the effect of smoking cessation on OS. Smoking cessation benefits OS merely for patients with high MAPRE3 expression.
Chao Chen, Jiancheng Cheng, Ruili Hou, Xiaoyuan Zheng, Li Su, Maria Moksnes Bjaanæs, Anna Karlsson, Maria Planck, Johan Staaf, Åslaug Helland, Manel Esteller, David C. Christiani, Feng Chen, Xiaofei Cao, Ruyang Zhang   +14 more
wiley   +1 more source

Sovereign AI supercomputers: a global landscape review of unprecedented biomedical research infrastructure. [PDF]

Front Artif Intell
Yang L, Bryan ME, Veiga E, Lowenhoff I, Wan A, Mina I, Allen T, Alfaro JA, Bloomfield G, Beach J, Dahlgren K, Davis NK, Fontana E, Gennatas S, Ghafoor Q, Housseau F, Lubelski D, Zhang Z, Hancock M, Ince W, James D, Khan S, Kunene V, McGrane J, Millen GC, Moxley-Wyles B, Narganes-Carlon D, Payne M, Ross PJ, Roux R, Rowe M, Lee R, Lee JSH, Liu JKH, Aggarwal D, Teoh ABS, Thirlwell C, Tilby M, Symeonides S, Watts I, Agus DB, Ono SJ, Elliott T, Calleja P, Lee LYW.   +44 more
europepmc   +1 more source

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

Molecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy, Jana Löptien, Cornelia Coith, Afroditi Nanou, Katharina Hintelmann, Pinnschmidt Hans, Cordula Petersen, Klaus Pantel, Sabine Riethdorf, Kerstin Borgmann, Harriet Wikman   +10 more
wiley   +1 more source

Molecular Quantum Computations on a Protein. [PDF]

J Chem Theory Comput
Shajan A, Kaliakin D, Liang F, Pellegrini T, Doga H, Bhowmik S, Das S, Mezzacapo A, Motta M, Merz KM.   +9 more
europepmc   +1 more source

Clinical performance of the urine‐based TERT promoter AbsoluteQ Digital PCR for non‐invasive detection of bladder cancer

Molecular Oncology, EarlyView.
A urine‐based digital PCR assay targeting two hotspot TERT promoter variants detected bladder cancer with high sensitivity and no false positives in this case–control cohort. The streamlined AbsoluteQ workflow outperformed Sanger sequencing and supports non‐invasive molecular testing for bladder cancer detection.
Anna Nykel, Izabela Kubiak, Lena Rutkowska, Żaneta Kasprzyk, Łukasz Kępczyński, Michał Bednarek, Dariusz Sobieraj, Jacek Wilkosz, Piotr Kania, Adam Jędrzejczyk, Bogdan Kałużewski, Agnieszka Gach, Tadeusz Kałużewski   +12 more
wiley   +1 more source

Molecular Computation [PDF]

, 2012
Gabriela Juarez-Martinez, Alessandro Chiolerio, Paolo Allia, Martino Poggio, Christian L. Degen, Li Zhang, Bradley J. Nelson, Lixin Dong, Mitsumasa Iwamoto, Markus J. Buehler, Graham Bratzel, Farghalli A. Mohamed, Nathan Doble, Alok Govil, Ion Bita, Evgeni Gusev, Jung-Tang Huang, Kuo-Yu Lee, Hou-Jun Hsu, Pen-Shan Chao, Chung-Yi Lin, Jit Muthuswamy, Murat Okandan, Donald P. Butler, Zeynep Celik-Butler, Bongsang Kim, Woo-Tae Park, Anisullah Baig, Diana Gamzina, Jinfeng Zhao, Youngmin Shin, Robert Barchfeld, Larry R. Barnett, Calvin Domier, Neville C. Luhmann, Yitzhak Rosen, Pablo Gurman, Craig Snoeyink, Steven T. Wereley, Ranajay Ghosh, Aloke Kumar, Partha P. Mukherjee, Seonghwan Kim, Thomas Thundat, Ashwini Gopal, Kazunori Hoshino, John Xiaojing Zhang, Takahito Ono, Masayoshi Esashi, Soichiro Tsuda, Ryan M. Pocratsky, Maarten P. Boer, Shawn Litster, Clifford W. Padgett, Tad S. Whiteside, Luigi Preziosi, Soichiro Tsuda, Melissa A. Pasquinelli, Yaroslava G. Yingling, Yunfeng Shi, Stuart A. Boden, Darren M. Bagnall, Rita E. Serda, Mauro Ferrari   +63 more
openaire   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source